Show simple item record

dc.contributor.authorRiiser, Amund
dc.contributor.authorStensrud, Trine
dc.contributor.authorStang, Julie
dc.contributor.authorAndersen, Lars Bo
dc.date.accessioned2021-02-04T13:10:17Z
dc.date.available2021-02-04T13:10:17Z
dc.date.created2020-11-16T11:52:48Z
dc.date.issued2020
dc.identifier.citationRiiser, A., Stensrud, T., Stang, J., & Andersen, L. B. (2020). Can β2-agonists have an ergogenic effect on strength, sprint or power performance? Systematic review and meta-analysis of RCTs. British Journal of Sports Medicine, 54(22), 1351–1359.en_US
dc.identifier.issn0306-3674
dc.identifier.urihttps://hdl.handle.net/11250/2726186
dc.descriptionAuthor's accepted manuscript version. This article has been accepted for publication in British Journal of Sports Medicine 2020 following peer review, and the Version of Record can be accessed online at https://doi.org/10.1136/bjsports-2019-100708en_US
dc.description.abstractObjectives: We aimed to examine the effect of β2-agonists on anaerobic performance in healthy non-asthmatic subjects. Design: Systematic review and meta-analysis. Eligibility criteria: We searched four databases (PubMed, Embase, SPORTDiscus and Web of Science) for randomised controlled trials, published until December 2019, examining the effect of β2-agonists on maximal physical performance lasting 1 min or shorter. Data are presented as standardised difference in mean (SDM) with 95% confidence intervals (95% CI). Results: 34 studies were included in the present meta-analysis. The studies include 44 different randomised and placebo-controlled comparisons with β2-agonists comprising 323 participants in crossover trials, and 149 participants in parallel trials. In the overall analyses, β2-agonists improved anaerobic performance by 5% (SDM 0.29, 95% CI 0.16 to 0.42), but the effect was related to dose and administration route. In a stratified analysis, the SDM was 0.14 (95% CI 0.00 to 0.28) for approved β2-agonists and 0.46 (95% CI 0.24 to 0.68) for prohibited β2-agonists, respectively. Furthermore, SDM was 0.16 (95% CI 0.02 to 0.30) for inhaled administration and 0.51 (95% CI 0.25 to 0.77) for oral administration, respectively, and 0.20 (95% CI 0.07 to 0.33) for acute treatment and 0.50 (95% CI 0.20 to 0.80) for treatment for multiple weeks. Analyses stratified for the type of performance showed that strength (0.35, 95% CI 0.15 to 0.55) and sprint (0.17, 95% CI 0.06 to 0.29) performance were improved by β2-agonists. Conclusion/implication: Our study shows that non-asthmatic subjects can improve sprint and strength performance by using β2-agonists. It is uncertain, however, whether World Anti-Doping Agency (WADA)-approved doses of β2-agonists improve performance. Our results support that the use of β2-agonists should be controlled and restricted to athletes with documented asthma.en_US
dc.language.isoengen_US
dc.publisherBMJ Publishing Groupen_US
dc.titleCan β2-agonists have an ergogenic effect on strength, sprint or power performance? Systematic review and meta-analysis of RCTsen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionacceptedVersionen_US
dc.rights.holder© Author(s) (or their employer(s)) 2020en_US
dc.source.pagenumber1351-1359en_US
dc.source.volume54en_US
dc.source.journalBritish Journal of Sports Medicineen_US
dc.source.issue22en_US
dc.identifier.doi10.1136/bjsports-2019-100708
dc.identifier.cristin1848284
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode2


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record